Chronic lymphocytic leukaemia+1
RecruitingStudy Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors
Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors
- Disease:Chronic lymphocytic leukaemiaB-cell small lymphocytic lymphoma
- Substances:BGB-16673Idelalisib+3
Italy- Participants:18–64 years · 65+ years
- Substances:BGB-16673
- Sponsor:BeOne Medicines AG











